SUBSCRIBERS
Amgen discounts cholesterol drug, but payers want more
Published Sun, Mar 19, 2017 · 09:50 PM
New York
AMGEN Inc sells its cholesterol-lowering drug Repatha at a discount of about 30 per cent to its US list price of US$14,000 a year, but the largest pharmacy benefit managers say they want lower prices after new data suggested more patients should be treated with the drug.
Amgen, which on Friday presented data showing for the first time that Repatha cuts the ris…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cordlife requests trading halt after dropping 15.2% to all-time low, pending announcement
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain